Chemotherapy regimens received by women with brca1/2 pathogenic variants for early stage breast cancer treatment

HIGHLIGHTS

• who: JNCI Cancer Spectrum ( and collaborators from the DepartmentStanford University, Atlanta, GA, USA have published the paper: Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment, in the Journal: (JOURNAL) of May/27,/2022

SUMMARY

The authors recently published on breast cancer-specific mortality among women with stages I-IV breast cancer who received chemotherapy according to SEER records and linked to a genetic testing result from any of the 4 partnering laboratories. For the current study, the authors excluded patients with HER2-positive breast cancer . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.